NATO Backs Dutch Medical Startup to Transform Infection Detection in Conflict Zones
Amsterdam, Thursday 2 April 2026
Marking its first Dutch investment, NATO’s Innovation Fund has backed Inbiome with $16 million to slash bacterial infection detection times from days to just five hours in conflict zones.
Revolutionising Battlefield and Clinical Diagnostics
On 1 April 2026, the NATO Innovation Fund (NIF) formally announced its co-leadership of a Series A financing round for the Dutch molecular diagnostics company Inbiome, working alongside a consortium led by Slingshot Ventures [2]. The funding, reported as a USD 16 million Series A by the NIF [2] and cited as €16 million in total raised capital by Dutch financial media [1], represents the NIF’s inaugural investment in a Netherlands-based enterprise [1][2]. Established under the NATO 2030 initiative, the NIF deploys a war chest exceeding €1 billion, backed by 24 allied nations—notably excluding the United States—to support deeptech startups addressing critical defence, security, and resilience challenges [1].
Strategic Resilience and Dual-Use Applications
For military operations, rapid diagnostics are a matter of strategic resilience. Injured personnel are highly susceptible to severe infections in battlefield environments, where delayed treatment can lead to fatal complications or necessitate complex, high-risk medical evacuations [1][2]. Amalia Kontesi, Chief Communications and Marketing Officer at the NIF, highlighted that NATO recognises substantial opportunities to enhance infection diagnostics on active war fronts, explicitly noting the ongoing situation in Ukraine [1]. By delivering species-level pathogen identification directly in conflict zones, the technology aims to reduce hospital stays and lower overall healthcare costs [2].
Regulatory Milestones and Commercial Expansion
Inbiome’s transition from laboratory research to market implementation is already well underway. The company’s Molecular Culture ID platform secured In Vitro Diagnostic Regulation (IVDR) certification in April 2025 [2]. Currently, the system is actively deployed in collaborations across more than 20 hospitals throughout Europe and the United States [2]. To further guide its commercial scaling and clinical integration, the company has appointed Michiel Boehmer, the former Chief Executive Officer of Unilabs, as a strategic advisor [2].